<DOC>
	<DOCNO>NCT00000344</DOCNO>
	<brief_summary>The purpose study determine efficacy safety buprenorphine/naloxone sublingual tablet formulation office-based therapy opiate-dependence treatment .</brief_summary>
	<brief_title>Buprenorphine/Naloxone Treatment Opiate Dependence - 9</brief_title>
	<detailed_description />
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<criteria>M/F age 2150 . Meet DSMIV criterion opiate dependence . Agree condition study sign inform consent . Psychiatric disorder require medication therapy . History seizure . Pregnant and/or nuring woman . Dependence ETOH benzodiazepine sedative/hypnotics . Acute hepatitis . Other medical condtions deem participation unsafe .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>opioid dependence</keyword>
</DOC>